In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma (NASDAQ: CPRX), with a price target of $6. The company’s shares closed yesterday at $2.76.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.5% and a 48.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Catalyst Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.51 and a one-year low of $1.81. Currently, Catalyst Pharma has an average volume of 727.5K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CPRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder.
